Open AccessNew York University School of Medicine Drug Development Educational Program: 2‐Year Benchmark
Author(s) -
Plaksin J,
Cymerman RM,
Caso Caso R,
Galeano C,
Ramasamy R,
Goldvon Simson G
Publication year - 2016
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12410
Subject(s) - drug development , benchmark (surveying) , medicine , medical education , drug , medline , gerontology , political science , pharmacology , geography , geodesy , law
Drug development (DD) is a multidisciplinary process that spans the translational continuum, yet remains an understudied entity in medical schools and biomedical science institutes. In response to a growing interest and unmet need, we implemented a DD course series that details identification of viable molecular targets, clinical trial design, intellectual property, and marketing. Enrollment is open to faculty, postdoctoral trainees, and MD, PhD, and MS students. After 2 years, 37 students and 23 students completed the fall and spring courses, respectively. Pre/post‐surveys demonstrated gained knowledge across course topics, with mean survey scores increased by 66% ( p < 0.001) after each course. Lectures for each course were consistently rated highly, with a mean course rating of 4.1/5. Through this program, trainees will have a more innovative approach toward identification of therapeutic targets and modalities. Furthermore, they will learn to integrate technology and biomedical informatics to find creative solutions in the DD process.